Physician profile
David M Larson
NPI 1609164391
$616.00
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.40 · 2022: $64.00 · 2023: $317 · 2024: $39.07 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $154.92 | 2023 | |
| Amgen INC. | $120.91 | 2023 | Repatha |
| Medline Industries LP | $76.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $61.14 | 2023-2024 | Quviviq |
| Lucid Diagnostics INC. | $47.25 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.87 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $19.02 | 2025 | Invega Sustenna |
| Itamar Medical INC | $18.86 | 2024 | Watchpatone |
| Novartis Pharmaceuticals Corporation | $17.09 | 2022 | |
| Lilly USA, LLC | $16.63 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.